Perth, Oct 29, 2007 (ABN Newswire) - HELICON GROUP LIMITED (ASX: HCG) announced today that the Chinese regulatory authority, the State Food and Drug Administration (SFDA) has formally accepted Helicon’s dossier seeking marketing approval for the China market for ReCell(R).
